Findings

What do systematic reviews say?

10 questions · 11 findings · 2 reviews · Headline outcomes only

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 27.3%High 8 · 72.7%

Intervention not reported

Etanercept (10 mg) · participants with rheumatoid arthritis

The intervention leads to lower etanercept (10 mg) (high certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 0.76 [0.58, 0.99]
1 study · 423 participants
High

Intervention not reported

Etanercept (25 mg) · participants with rheumatoid arthritis

The intervention leads to higher etanercept (25 mg) (high certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 7.95 [2.94, 21.47]
1 study · 158 participants
High

Intervention not reported

Etanercept (10 mg) · participants with rheumatoid arthritis

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 425 participants
High

Intervention not reported

Etanercept (25 mg) · participants with rheumatoid arthritis

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
1 study · 424 participants
High

Any systemic treatment vs placebo

Etanercept · people with chronic plaque psoriasis

Any systemic treatment probably leads to higher etanercept compared with placebo (moderate certainty).

2 findings from 1 review

Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes only
RR 9.72 [8.12, 11.63]
14 studies · 5650 participants
Moderate
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis 2020 · Cochrane Headline outcomes only
RR 0.89 [0.61, 1.31]
13 studies · 4265 participants
Moderate

Intervention not reported

Etanercept vs. DMARD · participants with rheumatoid arthritis

The intervention leads to higher etanercept vs. DMARD (high certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 1.17 [1.02, 1.35]
3 studies · 1112 participants
High

Intervention not reported

Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis

The intervention leads to higher etanercept (25 mg) + DMARD (high certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 1.52 [1.36, 1.7]
2 studies · 958 participants
High

Intervention not reported

Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 894 participants
High

Intervention not reported

Etanercept + DMARD vs. DMARD · participants with rheumatoid arthritis

The intervention leads to higher etanercept + DMARD vs. DMARD (high certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 2.82 [1.71, 4.68]
5 studies · 1118 participants
High

Intervention not reported

Etanercept + DMARD vs. Etanercept · participants with rheumatoid arthritis

The intervention probably leads to higher etanercept + DMARD vs. Etanercept (moderate certainty).

1 finding from 1 review

Etanercept for the treatment of rheumatoid arthritis 2013 · Cochrane Headline outcomes only
RR 1.44 [1.16, 1.79]
3 studies · 805 participants
Moderate